Coyle D
Health Econ Rev. 2024; 14(1):90.
PMID: 39532792
PMC: 11559153.
DOI: 10.1186/s13561-024-00556-w.
Muir J, Radhakrishnan A, Ozer Stillman I, Sarri G
Clinicoecon Outcomes Res. 2024; 16:581-596.
PMID: 39184340
PMC: 11344546.
DOI: 10.2147/CEOR.S471827.
Ward T, Mujica-Mota R, Spencer A, Medina-Lara A
Pharmacoeconomics. 2021; 40(1):45-64.
PMID: 34713423
DOI: 10.1007/s40273-021-01094-7.
Turner H, Archer R, Downey L, Isaranuwatchai W, Chalkidou K, Jit M
Front Public Health. 2021; 9:722927.
PMID: 34513790
PMC: 8424074.
DOI: 10.3389/fpubh.2021.722927.
Iyer H, Wolf N, Flanigan J, Castro M, Schroeder L, Fleming K
Health Policy Plan. 2021; 36(7):1116-1128.
PMID: 34212191
PMC: 8359747.
DOI: 10.1093/heapol/czab078.
A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann B, Eichinger J, Baumgartner M
Orphanet J Rare Dis. 2021; 16(1):292.
PMID: 34193232
PMC: 8247078.
DOI: 10.1186/s13023-021-01925-y.
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
Blonda A, Denier Y, Huys I, Simoens S
Front Pharmacol. 2021; 12:631527.
PMID: 34054519
PMC: 8150002.
DOI: 10.3389/fphar.2021.631527.
Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs.
Pitt A, Goldhaber-Fiebert J, Brandeau M
Med Decis Making. 2020; 40(8):978-989.
PMID: 32996356
PMC: 8056742.
DOI: 10.1177/0272989X20960458.
Systematic review of economic evaluations of interventions for high risk young people.
Edmunds K, Ling R, Shakeshaft A, Doran C, Searles A
BMC Health Serv Res. 2018; 18(1):660.
PMID: 30139384
PMC: 6108123.
DOI: 10.1186/s12913-018-3450-x.
Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.
Boujaoude M, Mirelman A, Dalziel K, Carvalho N
Cost Eff Resour Alloc. 2018; 16:18.
PMID: 29796012
PMC: 5960127.
DOI: 10.1186/s12962-018-0102-2.
Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.
Dukhanin V, Searle A, Zwerling A, Dowdy D, Taylor H, Merritt M
Soc Sci Med. 2017; 198:27-35.
PMID: 29274616
PMC: 6545595.
DOI: 10.1016/j.socscimed.2017.12.012.
Economic evaluations of vaccines in Canada: a scoping review.
Rafferty E, Gagnon H, Farag M, Waldner C
Cost Eff Resour Alloc. 2017; 15:7.
PMID: 28484344
PMC: 5420143.
DOI: 10.1186/s12962-017-0069-4.
Using Cost-Effectiveness Analysis to Address Health Equity Concerns.
Cookson R, Mirelman A, Griffin S, Asaria M, Dawkins B, Norheim O
Value Health. 2017; 20(2):206-212.
PMID: 28237196
PMC: 5340318.
DOI: 10.1016/j.jval.2016.11.027.
The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
Skedgel C
Curr Oncol. 2016; 23(5):322-328.
PMID: 27803596
PMC: 5081008.
DOI: 10.3747/co.23.3033.
Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings.
Rutstein S, Price J, Rosenberg N, Rennie S, Biddle A, Miller W
Glob Public Health. 2016; 12(10):1269-1281.
PMID: 27141969
PMC: 5303190.
DOI: 10.1080/17441692.2016.1178319.
Economic evaluation of mental health interventions: an introduction to cost-utility analysis.
Luyten J, Naci H, Knapp M
Evid Based Ment Health. 2016; 19(2):49-53.
PMID: 27075444
PMC: 10699413.
DOI: 10.1136/eb-2016-102354.
Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis.
Norheim O, Baltussen R, Johri M, Chisholm D, Nord E, Brock D
Cost Eff Resour Alloc. 2014; 12:18.
PMID: 25246855
PMC: 4171087.
DOI: 10.1186/1478-7547-12-18.
Prioritising health service innovation investments using public preferences: a discrete choice experiment.
Erdem S, Thompson C
BMC Health Serv Res. 2014; 14:360.
PMID: 25167926
PMC: 4166469.
DOI: 10.1186/1472-6963-14-360.
Social and material deprivation and the cost-effectiveness of an intervention to promote physical activity: cohort study and Markov model.
Gulliford M, Charlton J, Bhattarai N, Rudisill C
J Public Health (Oxf). 2014; 36(4):674-83.
PMID: 24482061
PMC: 4245899.
DOI: 10.1093/pubmed/fdt132.
Lifetime QALY prioritarianism in priority setting: quantification of the inherent trade-off.
Ottersen T, Maestad O, Norheim O
Cost Eff Resour Alloc. 2014; 12(1):2.
PMID: 24418267
PMC: 3896665.
DOI: 10.1186/1478-7547-12-2.
